Linked Life Data

11735093

Source:http://linkedlifedata.com/resource/pubmed/id/11735093

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
12
pubmed:dateCreated
2001-12-5
pubmed:abstractText
Hyperinsulinemia and insulin resistance are common features of obesity in humans and experimental animals. It has been demonstrated that metformin, an antihyperglycemic agent, decreases hyperinsulinemia and insulin resistance leading to decreased adiposity in obese and non-insulin-dependent diabetes mellitus (NIDDM) adults. To evaluate the antiobesity effect of metformin, we conducted a randomized double-blind placebo controlled trial in 24 hyperinsulinemic nondiabetic obese adolescents (body mass index [BMI] >30 kg/m(2)). All subjects were placed on a low-calorie (1,500 kcal for women and 1,800 kcal for men) meal plan. After an initial 1-week lead-in period, 12 subjects (mean +/- SE for age and BMI, 15.6 +/- 0.4 and 41.2 +/- 1.8, respectively) received metformin (850 mg twice daily) for 8 weeks, and 12 subjects (mean +/- SE for age and BMI, 15.7 +/- 0.5 and 40.8 +/- 1.4, respectively) received placebo. Compared to the placebo group, the metformin group had greater weight loss (6.5% +/- 0.8% v 3.8 +/- 0.4%, P <.01), greater decrease in body fat (P <.001), greater increase in fat-free mass to body fat ratio (P <.005), and greater attenuation of area under the curve (AUC) insulin response to an oral glucose tolerance test (P <.001). This was associated with enhanced insulin sensitivity, as determined by the fasting plasma glucose:insulin, 2-hour glucose:insulin, and AUC glucose:AUC insulin ratios, in the metformin group compared to controls (P <.01). This corresponded to a significant reduction in plasma leptin (P <.005), cholesterol, triglycerides, and free fatty acid (FFA) levels (P <.05) only in the metformin-treated subjects. Combined metformin treatment and low-calorie diet had a significant antiobesity effect in hyperinsulinemic obese adolescents compared to a low-calorie diet alone.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Dec
pubmed:issn
0026-0495
pubmed:author
pubmed:copyrightInfo
Copyright 2001 by W.B. Saunders Company
pubmed:issnType
Print
pubmed:volume
50
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1457-61
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed-meshheading:11735093-Adipose Tissue, pubmed-meshheading:11735093-Adolescent, pubmed-meshheading:11735093-Blood Glucose, pubmed-meshheading:11735093-Body Composition, pubmed-meshheading:11735093-Body Mass Index, pubmed-meshheading:11735093-Cholesterol, pubmed-meshheading:11735093-Diet, Reducing, pubmed-meshheading:11735093-Double-Blind Method, pubmed-meshheading:11735093-Energy Intake, pubmed-meshheading:11735093-Fasting, pubmed-meshheading:11735093-Fatty Acids, Nonesterified, pubmed-meshheading:11735093-Female, pubmed-meshheading:11735093-Glucose Tolerance Test, pubmed-meshheading:11735093-Humans, pubmed-meshheading:11735093-Hyperinsulinism, pubmed-meshheading:11735093-Hypoglycemic Agents, pubmed-meshheading:11735093-Kinetics, pubmed-meshheading:11735093-Leptin, pubmed-meshheading:11735093-Male, pubmed-meshheading:11735093-Metformin, pubmed-meshheading:11735093-Obesity, Morbid, pubmed-meshheading:11735093-Placebos, pubmed-meshheading:11735093-Triglycerides, pubmed-meshheading:11735093-Weight Loss
pubmed:year
2001
pubmed:articleTitle
Beneficial effects of metformin in normoglycemic morbidly obese adolescents.
pubmed:affiliation
Department of Pediatrics, University of Tennessee, Graduate School of Medicine, Knoxville, TN, USA.
pubmed:publicationType
Journal Article, Clinical Trial, Randomized Controlled Trial, Research Support, Non-U.S. Gov't